Sinequan is a brand name for doxepin, a tricyclic antidepressant that has been prescribed since the 1960s for depression, anxiety, and chronic pain. What makes doxepin unusual among older antidepressants is its second life: at very low doses, it earned FDA approval for insomnia in 2010, and a topical cream form is used to treat severe itching. That range of applications, from psychiatric illness to sleep trouble to skin conditions, stems from how the drug interacts with different receptor systems depending on the dose.
How Sinequan Works
Like other tricyclic antidepressants, doxepin affects multiple chemical systems in the brain. At the higher doses used for depression (typically 75 to 150 mg per day, sometimes more), it blocks the reuptake of serotonin and norepinephrine, increasing the availability of those neurotransmitters at nerve synapses. That reuptake-blocking action is what drives its antidepressant effect, though it also touches histamine, acetylcholine, and adrenergic receptors, which is where many of its side effects come from.
The property that sets doxepin apart is its exceptionally strong binding to the histamine H1 receptor. Among all tricyclic antidepressants, doxepin has one of the highest affinities for H1 receptors, making it a selective H1 blocker at low doses.1PubMed Central. Therapeutic rationale for low dose doxepin in insomnia patients At doses of 1 to 6 mg, doxepin binds almost exclusively to histamine receptors and largely leaves serotonin, norepinephrine, and acetylcholine pathways alone. That selectivity matters because histamine is one of the brain’s key wakefulness signals, and blocking it promotes and maintains sleep without the broader neurochemical footprint that comes with higher antidepressant doses.2PubMed. Low-dose doxepin: in the treatment of insomnia
Use for Depression and Anxiety
At antidepressant doses, Sinequan is an effective treatment for both depression and anxiety, though it is no longer a first-line choice for most patients because newer drug classes tend to carry fewer side effects. Compared head-to-head with other tricyclics, doxepin’s mood-elevating effect is roughly on par with amitriptyline, and at doses producing similar response rates, it tends to cause fewer or less bothersome side effects than either amitriptyline or imipramine.3PubMed. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression Its strong sedating quality makes it particularly suited to patients whose depression comes bundled with anxiety or insomnia, since a single drug can address both the low mood and the inability to sleep.
Doxepin has also shown benefit for generalized anxiety on its own. A study in Chinese patients with generalized anxiety disorder found that low-dose doxepin cut anxiety scores by more than half over the treatment period.4PubMed Central. Clinical efficacy and safety of low-dose doxepin in Chinese patients with generalized anxiety disorder: A before–after study In older adults with depression, doxepin performed as well as trimipramine, another tricyclic, at relieving both depressive and anxious symptoms.5PubMed. A comparison of the cardiac safety and therapeutic efficacy of trimipramine versus doxepin in geriatric depressed patients
Where doxepin fits in the modern antidepressant landscape is a practical question. A large German drug-surveillance program found that serious adverse reaction rates for doxepin ran about 0.6 percent of patients, which was lower than clomipramine (around 2 percent) and on par with rates seen with SSRIs.6PubMed. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP That said, SSRIs and SNRIs remain preferred in most clinical guidelines because their overall side-effect burden and safety in overdose are more favorable than any tricyclic’s.
Low-Dose Sinequan for Insomnia
The low-dose insomnia formulation (marketed under the brand name Silenor, but sometimes prescribed generically) uses doxepin at just 3 or 6 mg, a fraction of the antidepressant dose. At these levels, the drug works almost purely as a histamine blocker, which is why it improves sleep without the anticholinergic and cardiovascular effects associated with higher doses. Clinical trials in adults with chronic insomnia found that doses of 1, 3, and 6 mg improved sleep onset, sleep maintenance, and early-morning awakening with minimal disruption to normal sleep architecture.7PubMed. Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin
Doxepin is the only tricyclic antidepressant that has been rigorously studied in randomized, placebo-controlled trials for insomnia in both younger and older adults.8PubMed Central. Therapeutic rationale for low dose doxepin in insomnia patients That matters because many other sedating antidepressants (trazodone being the most common) are widely prescribed for sleep despite having far less formal evidence behind them at the specific doses used for insomnia.
One advantage of low-dose doxepin for insomnia is its effect on daytime mental sharpness. A study comparing doxepin to zolpidem (the active ingredient in Ambien) found that both drugs improved sleep quality, but doxepin led to better executive function performance the next day.9PubMed. Doxepin is more effective than zolpidem in improving executive function in patients with insomnia disorder That finding aligns with the general concern that some sedative-hypnotic drugs impair cognition in ways that linger after waking, a problem that low-dose doxepin appears to avoid.
How It Stacks Up Against Other Sleep Medications
A large network meta-analysis covering 153 randomized trials compared the effectiveness and safety of various insomnia drugs. Low-dose doxepin was among the treatments with relatively good effectiveness, tolerability, and lower risk of adverse events, alongside certain orexin receptor antagonists like suvorexant and lemborexant.10PubMed. The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials Antidepressants as a class significantly improved total sleep time compared to placebo, both by patients’ own reports and by objective measurement in sleep labs.
For people wary of the dependence potential of benzodiazepines and even the “Z-drugs” like zolpidem, doxepin offers a meaningful alternative. It does not work on the same receptor system that makes benzodiazepines habit-forming, and there is no evidence of rebound insomnia when it is stopped at low doses. It also does not carry the complex sleep behavior warnings (sleepwalking, sleep-driving) that are associated with some other hypnotics, though drowsiness the next morning can occur, especially in people who metabolize the drug slowly.
Topical Sinequan for Itching
Doxepin cream (5 percent) is approved for the short-term management of moderate itching in conditions like eczema and other forms of dermatitis. It works topically as both an H1 and H2 histamine blocker, which gives it a broader antihistamine effect on the skin than over-the-counter options that only block H1.11Journal of the American Academy of Dermatology. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream The cream is typically applied three or four times daily, and the main local side effect is a brief stinging sensation at the application site.
One caution with topical doxepin is that it can be absorbed through the skin in amounts sufficient to cause drowsiness, especially if applied to large body surface areas or to broken skin. Patients using the cream are usually advised not to cover treated areas with occlusive dressings and to be aware of sedation as a possible systemic effect. The cream is generally recommended for no more than eight days of continuous use.
Off-Label Uses
Tricyclic antidepressants as a class have a long track record in chronic pain management, and doxepin is no exception. It is used off-label for conditions like chronic facial pain, neuropathic pain, and fibromyalgia, typically at doses lower than those used for depression. Common side effects at these doses include dry mouth, sedation, constipation, and dizziness upon standing.12PubMed. The use of tricyclic antidepressants for the control of chronic orofacial pain
Irritable bowel syndrome is another condition where tricyclics, including doxepin, have shown benefit. A meta-analysis found that low-dose tricyclic antidepressants nearly doubled the likelihood of clinical improvement in IBS compared to placebo and produced a large reduction in abdominal pain scores.13PubMed Central. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis The mechanism likely involves the drugs’ effects on pain signaling in the gut-brain axis rather than their antidepressant action, since the doses used are often too low to treat depression.
In post-stroke depression, a network meta-analysis ranked doxepin as the most effective antidepressant among those studied, ahead of paroxetine and nortriptyline, all of which outperformed placebo. However, doxepin was also less well tolerated than paroxetine or placebo in that population, meaning patients were more likely to drop out of treatment due to side effects.14Brazilian Journal of Medical and Biological Research. Efficacy, acceptability, and tolerability of antidepressant treatments for patients with post-stroke depression: a network meta-analysis That tradeoff between strong efficacy and limited tolerability captures the broader story of tricyclics in modern medicine: they work well, but their side-effect profile limits who can comfortably take them.
Side Effects and What to Expect
The side effects of Sinequan are dose-dependent, which is a point that often gets lost when the drug is discussed as a single entity. At antidepressant doses (75 mg and above), the profile includes the classic tricyclic complaints: dry mouth, drowsiness, constipation, blurred vision, urinary retention, weight gain, and drops in blood pressure when standing. These effects stem from the drug’s activity at muscarinic acetylcholine receptors and alpha-adrenergic receptors, which are strongly engaged at higher doses.
At low insomnia doses (3 to 6 mg), most of these side effects are absent or minimal because the drug is essentially only blocking histamine. The most commonly reported issue is next-morning drowsiness, and even that tends to be less pronounced than with many competing sleep aids. The contrast between the two dose ranges is so stark that low-dose doxepin and high-dose doxepin almost behave like different medications.
Weight gain deserves specific mention because it is one of the more persistent complaints among people taking doxepin at antidepressant doses over the long term. Histamine H1 blockade is itself associated with increased appetite, and this effect is amplified at higher doses where other receptor interactions compound the issue. If you are prescribed Sinequan for depression and notice steady weight gain, that is a recognized effect worth discussing with your prescriber rather than something to accept silently.
Overdose Risks and Heart Safety
Like all tricyclic antidepressants, doxepin is dangerous in overdose. The drug blocks fast sodium channels and delayed rectifier potassium channels in the heart, which can widen the QRS complex and prolong the QT interval on an electrocardiogram.15American Journal of Respiratory and Critical Care Medicine. A102-10 Bradycardia Masking Dual Sodium and Potassium Channel Blockade: An ED-ICU-Toxicology Collision in Clonidine and Doxepin Overdose In practical terms, this means that taking too much doxepin can cause life-threatening heart rhythm disturbances. A large analysis of drug overdoses found that doxepin was among the medications associated with an increased risk of severe QT prolongation.16PubMed Central. Drug-specific risk of severe QT prolongation following acute drug overdose
This toxicity in overdose is one reason why tricyclics, including Sinequan, are prescribed more cautiously to patients considered at risk for self-harm. It is also why prescribers often limit the quantity dispensed at any one time. At therapeutic doses, heart effects are generally manageable, but an EKG baseline and periodic monitoring are sometimes recommended, especially in older adults or people with pre-existing heart conditions.
Special Concerns for Older Adults
Doxepin at antidepressant doses has long been flagged as potentially inappropriate for older adults. The Beers Criteria, a widely referenced list of medications that carry extra risks for people over 65, includes Sinequan specifically because of its strong anticholinergic and sedating properties.17JAMA Internal Medicine. Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults In older adults, anticholinergic drugs can worsen confusion, increase fall risk, cause urinary retention, and contribute to cognitive decline over time. For these reasons, doxepin at antidepressant doses is rarely the first choice for geriatric depression.
Here is where it gets counterintuitive: the Beers Criteria caution applies primarily to the high-dose antidepressant form. Low-dose doxepin (6 mg or less) for insomnia was specifically studied in elderly populations and is generally considered acceptable. The anticholinergic load at those tiny doses is negligible. So a geriatrician who would never prescribe Sinequan 100 mg for depression might comfortably prescribe 3 mg for sleep. If you are an older adult and see doxepin on a “medications to avoid” list, the context of the dose matters enormously.
How Your Genetics Affect Doxepin
Doxepin is metabolized in the liver primarily by CYP2D6, an enzyme whose activity varies widely across the population due to genetic differences. Some people are “poor metabolizers” who break down doxepin very slowly, leading to higher drug levels in the blood and a greater risk of side effects. Others are “ultrarapid metabolizers” who clear the drug quickly, potentially making standard doses less effective. Modeling work has shown that as CYP2D6 metabolic capacity decreases, doxepin exposure increases in a predictable, genotype-dependent pattern.18PubMed Central. PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy
This genetic variability is clinically meaningful. A person who is a poor CYP2D6 metabolizer might experience pronounced sedation, dry mouth, or dizziness at a dose that causes no issues for someone else. Pharmacogenomic testing is available and increasingly accessible, and some guidelines suggest testing CYP2D6 status before starting tricyclics at antidepressant doses. In practice, many prescribers still rely on clinical observation (starting low, adjusting based on response and side effects), but if you have had unusual reactions to medications metabolized by CYP2D6, mentioning that history to your prescriber is worth doing.
Drug interactions compound this variability. Medications that inhibit CYP2D6, such as fluoxetine, paroxetine, and bupropion, can slow doxepin metabolism and effectively turn a normal metabolizer into a poor one. If you are taking Sinequan and your prescriber adds or removes another medication, the effective dose of doxepin in your system may shift even though the pill you are taking has not changed.
Stopping Sinequan Safely
Abruptly stopping a tricyclic antidepressant after extended use can trigger a withdrawal syndrome. Symptoms that have been linked to tricyclic discontinuation include gastrointestinal distress (nausea, vomiting, cramping), sleep disturbances, excessive sweating, headache, restlessness, and in some cases involuntary movements or mood instability.19PubMed. Tricyclic antidepressant withdrawal syndrome The proposed mechanism involves a rebound overactivity of the cholinergic and adrenergic systems that were suppressed while the drug was on board.
The standard recommendation is to taper the dose gradually over weeks rather than stopping all at once. Tapering schedules vary by how long you have been on the drug and at what dose, but a common approach is to reduce the dose by about 25 percent every one to two weeks and hold at each new level long enough to assess whether withdrawal symptoms emerge. If symptoms do appear, slowing the taper or briefly stepping back to the previous dose usually resolves them. At low insomnia doses, withdrawal risk is considerably lower, though some prescribers still recommend a gradual reduction rather than an abrupt stop, particularly for patients who have been using it nightly for months.
Pregnancy and Breastfeeding
Data on doxepin in pregnancy are limited, and the drug is generally not a first-choice antidepressant for pregnant women. The bigger concern involves breastfeeding. A case report documented a nine-day-old infant who developed poor sucking, low muscle tone, drowsiness, and vomiting while being nursed by a mother taking doxepin. The infant’s immature liver was unable to clear doxepin and its active breakdown product efficiently, allowing the drug to accumulate.20PubMed. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin The conclusion from available evidence is that breastfeeding while on doxepin carries meaningful risk, especially for newborns whose liver metabolism is already reduced. Women who need an antidepressant while nursing are generally steered toward agents with more reassuring lactation data, such as sertraline.
If you are pregnant or planning to become pregnant while taking Sinequan, the decision to continue, switch, or taper involves weighing the risk of untreated depression or anxiety against the potential effects of the drug on the baby. That calculus is highly individual, and the answer is different for someone whose depression is mild and manageable without medication than for someone with severe or recurrent illness.
Why an Old Drug Still Gets Prescribed
Sinequan occupies an odd niche: it is a legacy tricyclic that most psychiatrists would not reach for first when treating depression, yet it keeps finding new relevance. Its low-dose insomnia indication gave it a second act that is grounded in more rigorous trial evidence than many competing off-label sleep prescriptions. Its topical form fills a gap for patients with dermatitis-related itching who do not respond to standard antihistamines. And for certain pain conditions, the tricyclic mechanism of action remains genuinely useful in ways that newer antidepressants do not replicate.
The drug also illustrates a broader pharmacological principle: the same molecule can do very different things at different doses. A patient taking 3 mg of doxepin for sleep and a patient taking 150 mg for depression are on what is, pharmacologically, almost two different medications acting on different receptor targets. That dose-dependent receptor selectivity is uncommon and is part of why doxepin has adapted to uses its original developers never anticipated.